View Clinical Trial (Medical Research Study)

A Study of LY2189265 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus on Metformin - NCT00734474-29412(Clinical Trial 236082)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Charleston
State:  
SC
Zip Code: 29412
Conditions: Diabetes Mellitus, Type 2
Purpose: This is an adaptive dose finding study and a phase 3 efficacy study to evaluate the effects of once weekly injection of LY2189265 compared to sitagliptin on glucose by measuring HbA1c change from baseline after twelve months in patients with type 2 diabetes mellitus on metformin.
Study summary:
Criteria: Inclusion Criteria: - Diabetes mellitus, type 2 for at least 6 months - Treatment regimens: diet and exercise, metformin as monotherapy or in combination with another oral antihyperglycemic medication (OAM), or another OAM as monotherapy. Must be able to tolerate metformin at a dose of at least 1500 mg daily for 6 weeks prior to randomization. - HbA1c value of ≥7.0% to ≤9.5% - Body mass index (BMI) between 25 and 40 kg/m2, inclusive - Stable weight for 3 months prior to screening - Females of childbearing potential must test negative for pregnancy and agree to use a reliable birth control method Exclusion Criteria: - Diabetes mellitus, type 1 - Use of a GLP-1 analog (for example, exenatide) within 6 months prior to screening or are being treated with insulin - Gastric emptying abnormality, history of bariatric surgery or chronic use of drugs that affect gastrointestinal motility - Use of medications to promote weight loss - Cardiovascular event within 6 months prior to screening - Poorly controlled hypertension - ECG reading considered outside the normal limits or indicating cardiac disease - Liver disease, hepatitis, chronic pancreatitis, idiopathic acute pancreatitis, or alanine transaminase (ALT) levels >3.0 times the upper limit of normal - Serum creatinine ≥1.5 mg/dL or a creatinine clearance < 60 ml/minute - Uncontrolled diabetes - Uncontrolled endocrine or autoimmune abnormality - History of a transplanted organ - Chronic use of systemic glucocorticoid therapy - Active or untreated malignancy - Use of CNS stimulants
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: August 16, 2010
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.